These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16919012)

  • 1. Endothelin and endothelin receptor antagonism in portopulmonary hypertension.
    Neuhofer W; Gülberg V; Gerbes AL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():54-61. PubMed ID: 16919012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of portopulmonary hypertension with bosentan: case report.
    Stähler G; von Hunnius P
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():62-6. PubMed ID: 16919013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C.
    Grander W; Eller P; Fuschelberger R; Tilg H
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():67-70. PubMed ID: 16919014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with inhaled iloprost and bosentan in portopulmonary hypertension.
    Hoeper MM; Seyfarth HJ; Hoeffken G; Wirtz H; Spiekerkoetter E; Pletz MW; Welte T; Halank M
    Eur Respir J; 2007 Dec; 30(6):1096-102. PubMed ID: 17652314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
    Beghetti M
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Channick RN; Sitbon O; Barst RJ; Manes A; Rubin LJ
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):62S-67S. PubMed ID: 15194180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.
    Sogni P; Moreau R; Gomola A; Gadano A; Cailmail S; Calmus Y; Clozel M; Lebrec D
    Hepatology; 1998 Sep; 28(3):655-9. PubMed ID: 9731554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension.
    Hiramoto Y; Shioyama W; Higuchi K; Arita Y; Kuroda T; Sakata Y; Nakaoka Y; Fujio Y; Yamauchi-Takihara K
    J Cardiol; 2009 Jun; 53(3):374-80. PubMed ID: 19477379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosentan.
    Mathier MA; Ishizawar D
    Expert Opin Pharmacother; 2010 Apr; 11(6):1023-34. PubMed ID: 20307226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin receptor antagonists for pulmonary arterial hypertension: an overview.
    Raja SG
    Cardiovasc Ther; 2010 Oct; 28(5):e65-71. PubMed ID: 20406243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension.
    Dhillon S; Keating GM
    Am J Cardiovasc Drugs; 2009; 9(5):331-50. PubMed ID: 19791841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current management approaches to portopulmonary hypertension.
    Savale L; O'Callaghan DS; Magnier R; Le Pavec J; Hervé P; Jaïs X; Seferian A; Humbert M; Simonneau G; Sitbon O
    Int J Clin Pract Suppl; 2011 Jan; (169):11-8. PubMed ID: 21176011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosentan for the treatment of adult pulmonary hypertension.
    Dwyer N; Kilpatrick D
    Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosentan therapy for pulmonary arterial hypertension associated with hereditary haemorrhagic telangiectasia.
    Bonderman D; Nowotny R; Skoro-Sajer N; Adlbrecht C; Lang IM
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():71-2. PubMed ID: 16919015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?
    Kuntzen C; Gülberg V; Gerbes AL
    Gastroenterology; 2005 Jan; 128(1):164-8. PubMed ID: 15633133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosentan.
    Chin K; Channick R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosentan therapy for portopulmonary hypertension.
    Hoeper MM; Halank M; Marx C; Hoeffken G; Seyfarth HJ; Schauer J; Niedermeyer J; Winkler J
    Eur Respir J; 2005 Mar; 25(3):502-8. PubMed ID: 15738295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin-receptor antagonist treatment of portopulmonary hypertension.
    Hinterhuber L; Graziadei IW; Kähler CM; Jaschke W; Vogel W
    Clin Gastroenterol Hepatol; 2004 Nov; 2(11):1039-42. PubMed ID: 15551258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.